The estimated Net Worth of John Edward Lynch is at least $50.3 Thousand dollars as of 31 May 2022. John Lynch owns over 37,500 units of IGC Pharma Inc stock worth over $50,333 and over the last 2 years John sold IGC stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
John Lynch IGC stock SEC Form 4 insiders trading
John has made over 1 trades of the IGC Pharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently John exercised 37,500 units of IGC stock worth $14,044 on 31 May 2022.
The largest trade John's ever made was exercising 37,500 units of IGC Pharma Inc stock on 31 May 2022 worth over $14,044. On average, John trades about 37,500 units every 0 days since 2022. As of 31 May 2022 John still owns at least 134,401 units of IGC Pharma Inc stock.
You can see the complete history of John Lynch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at IGC Pharma Inc
Over the last 17 years, insiders at IGC Pharma Inc have traded over $12,397,736 worth of IGC Pharma Inc stock and bought 1,543,722 units worth $473,972 . The most active insiders traders include Ram Mukunda, Steven Michael Oliveira, and Zwirn & Co., L.P.Zwirn Dani.... On average, IGC Pharma Inc executives and independent directors trade stock every 143 days with the average trade being worth of $93,624. The most recent stock trade was executed by Ram Mukunda on 13 March 2024, trading 1,184,585 units of IGC stock currently worth $443,627.
What does IGC Pharma Inc do?
igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
What does IGC Pharma Inc's logo look like?
Complete history of John Lynch stock trades at IGC Pharma Inc
IGC Pharma Inc executives and stock owners
IGC Pharma Inc executives and other stock owners filed with the SEC include:
-
Ram Mukunda,
Exec. Chairman, Pres & CEO -
Claudia Grimaldi,
Vice President, Principal Financial Officer -
Claudia Grimaldi,
VP & Principal Financial Officer -
Richard Prins,
Independent Chairman of the Board -
Rohit Goel,
Manager and Principal Accounting Officer -
Dr. Ranga C. Krishna M.D.,
Sr. Advisor -
Parveen Mukunda,
Corp. Sec. -
Rohit Goel,
Sr. Director of Accounting & Principal Accounting Officer -
John Edward Lynch,
Director -
John Cherin,
CFO, Treasurer and PAO -
Sudhakar V Shenoy,
Director -
Ranga C Krishna,
Director -
Terry L Lierman,
Director -
Shu Kwong Ngai,
Interim CFO -
Zwirn & Co., L.P.Zwirn Dani...,
-
Acquisition Master Fund Ltd...,
10% owner -
Suhail Nathani,
Director -
Ag Ubs,
10% owner -
Steven Michael Oliveira,
10% owner -
Master Fund Ltd. Nisswa,
10% owner -
Ram Mukunda,
CEO -
Strategic Investment Fund A...,
10% owner -
James P Moran,
Director